Determination of dual delivery for stem cell differentiation using dexamethasone and TGF-beta3 in/on polymeric microspheres.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19539364.
- Also identified by DOI 10.1016/j.biomaterials.2009.05.054.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this work, a cocktail of dexamethasone (Dex) and transforming growth factor-beta3 (TGF-beta3) bound with heparin in/on PLGA microspheres was investigated by local dual delivery using rabbit mesenchymal stem cells (rMSCs) for chondrogenic differentiation in in vitro and in vivo study. In this study, we proved that the microsphere constructs were capable of simultaneously releasing TGF-beta3-conjugated with cy5.5 and Dex-conjugated with FITC with approximately zero order kinetics determined by Kodak imaging and confocal laser microscope. Microsphere constructs containing TGF-beta3 and Dex showed a significantly higher number of specific lacunae phenotypes at the end of the 4 week study irrespective of the presence of dexamethasone and TGF-beta3. Thus, dual delivery of TGF and Dex can be used to engineer inflammation-free and cartilage-associate tissue in the transplanted PLGA construct into nude mouse. These heparin-bound TGF-beta3-coated and Dex-loaded PLGA microsphere constructs show promise as coatings for implantable biomedical devices to improve biocompatibility and ensure both in vitro and in vivo performance.
Medical subject headings
- Cell Differentiation
- Dexamethasone
- Drug Delivery Systems
- Lactic Acid
- Mesenchymal Stem Cells
- Microspheres
- Polyglycolic Acid
- Transforming Growth Factor beta3